RxDoctor Payments Data

Shannon Hoffman

Family · Laurel, MSNPI 1316517063

Payments from drug & device makers

$611in general payments, 2019–2025

Across 37 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$195
  • AstraZeneca$175
  • AbbVie$69
  • Lilly USA, LLC$65
  • Boehringer Ingelheim$51
  • GSK$32
  • plus $26 from 1 others

What the payments were for

  • Food & beverage$611100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$611 in reported general payments places this provider in the 60th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$31,298
Medicare patients
127
Services billed
666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$46,789
TrulicityDulaglutide28$23,734
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$19,726
VraylarCariprazine Hcl12$17,454
JardianceEmpagliflozin14$16,720
MounjaroTirzepatide11$12,489
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,502
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$7,947
Albuterol Sulfate HfaAlbuterol Sulfate52$1,497
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,144
Gabapentin57$975
Atorvastatin Calcium111$831
ProgesteroneProgesterone, Micronized19$782
Metoprolol Succinate45$711
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort12$703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$195$46,78943 claims
Lilly USA, LLCTrulicity, Mounjaro$65$36,22339 claims
AstraZenecaBreztri Aerosphere$175$19,72622 claims
AbbVieVraylar$69$17,45412 claims
Boehringer IngelheimJardiance$51$16,72014 claims
GSKTrelegy Ellipta$32$11,50216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,007 family providers in Mississippi.

Other family in Laurel

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →